139 related articles for article (PubMed ID: 8836449)
21. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
Ogawa T; Sugidachi A; Asai F; Koike H
Blood Coagul Fibrinolysis; 1998 Apr; 9(3):233-40. PubMed ID: 9663705
[TBL] [Abstract][Full Text] [Related]
22. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.
Vanags DM; Rodgers SE; Duncan EM; Lloyd JV; Bochner F
Br J Pharmacol; 1992 Aug; 106(4):917-23. PubMed ID: 1393289
[TBL] [Abstract][Full Text] [Related]
23. Effects of urapidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets.
Storck J; Ochs JG; Kirsten R
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):303-8. PubMed ID: 2387654
[TBL] [Abstract][Full Text] [Related]
24. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells.
Kekewska A; Görnemann T; Jantschak F; Glusa E; Pertz HH
J Pharmacol Exp Ther; 2012 Feb; 340(2):369-76. PubMed ID: 22049464
[TBL] [Abstract][Full Text] [Related]
25. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
Herbert JM; Bernat A; Barthelemy G; Dol F; Rinaldi M
Thromb Haemost; 1993 Mar; 69(3):262-7. PubMed ID: 8470049
[TBL] [Abstract][Full Text] [Related]
26. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
[TBL] [Abstract][Full Text] [Related]
27. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
Porta C; Maiolo A; Tua A; Grignani G
Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928
[TBL] [Abstract][Full Text] [Related]
28. A potent 5-hydroxytryptamine receptor (5-HT2A) antagonist, DV-7028, delays arterial thrombosis development in rats.
Pawlak D; Pawlak K; Chabielska E; Małyszko J; Takada A; Myśliwiec M; Buczko W
Thromb Res; 1998 Jun; 90(6):259-70. PubMed ID: 9700856
[TBL] [Abstract][Full Text] [Related]
29. The role of serotonin in thrombogenesis.
De Clerck F
Clin Physiol Biochem; 1990; 8 Suppl 3():40-9. PubMed ID: 1966729
[TBL] [Abstract][Full Text] [Related]
30. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro.
Maayani S; Schwarz T; Craddock-Royal B; Tagliente TM
Platelets; 2001 Sep; 12(6):359-75. PubMed ID: 11672475
[TBL] [Abstract][Full Text] [Related]
31. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis.
Cohen ML; Robertson DW; Bloomquist WE; Wilson HC
J Pharmacol Exp Ther; 1992 Apr; 261(1):202-8. PubMed ID: 1560366
[TBL] [Abstract][Full Text] [Related]
32. Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries.
Bush LR
J Pharmacol Exp Ther; 1987 Feb; 240(2):674-82. PubMed ID: 3806419
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of Bulnesia sarmienti aqueous extract on agonist-induced platelet activation and thrombus formation involves mitogen-activated protein kinases.
Kamruzzaman SM; Endale M; Oh WJ; Park SC; Kim KS; Hong JH; Kwak YS; Yun BS; Rhee MH
J Ethnopharmacol; 2010 Aug; 130(3):614-20. PubMed ID: 20558266
[TBL] [Abstract][Full Text] [Related]
34. Induction of platelet aggregation in vitro by microbubbles of nitrogen.
Thorsen T; Lie RT; Holmsen H
Undersea Biomed Res; 1989 Nov; 16(6):453-64. PubMed ID: 2603242
[TBL] [Abstract][Full Text] [Related]
35. Platelet 5-HT2A-receptor-mediated induction of aggregation is not altered in major depression.
Gómez-Gil E; Gastó C; Díaz-Ricart M; Carretero M; Salamero M; Catalán R; Escolar G
Hum Psychopharmacol; 2002 Dec; 17(8):419-24. PubMed ID: 12457378
[TBL] [Abstract][Full Text] [Related]
36. Covalent complexes of albumin with serotonin, ketanserin and lysergic acid antagonize the activity of serotonin in human platelets.
VandenBerg SR; Gonias SL
Life Sci; 1989; 44(23):1777-85. PubMed ID: 2733551
[TBL] [Abstract][Full Text] [Related]
37. [Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats].
Xu HL; Feng YP
Yao Xue Xue Bao; 2001 May; 36(5):329-33. PubMed ID: 12584852
[TBL] [Abstract][Full Text] [Related]
38. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist.
Hara H; Osakabe M; Kitajima A; Tamao Y; Kikumoto R
Thromb Haemost; 1991 Apr; 65(4):415-20. PubMed ID: 2057925
[TBL] [Abstract][Full Text] [Related]
39. Effects of serotonin on platelet activation in whole blood.
Li N; Wallén NH; Ladjevardi M; Hjemdahl P
Blood Coagul Fibrinolysis; 1997 Nov; 8(8):517-23. PubMed ID: 9491270
[TBL] [Abstract][Full Text] [Related]
40. How can we inhibit 5-HT-induced platelet aggregation and why should we bother?
Heptinstall S; Bevan J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):475-8. PubMed ID: 2465956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
